{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:34:00Z","timestamp":1784529240499,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00204-021-03221-x","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T08:02:43Z","timestamp":1646035363000},"page":"1437-1453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Non-clinical immunogenicity, biodistribution and toxicology evaluation of a chimpanzee adenovirus-based COVID-19 vaccine in rat and rhesus macaque"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8211-2660","authenticated-orcid":false,"given":"Xuedong","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhuan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"issue":"3","key":"3221_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1128\/CVI.00609-15","volume":"23","author":"PL Acosta","year":"2015","unstructured":"Acosta PL, Caballero MT, Polack FP (2015) Brief history and characterization of enhanced respiratory syncytial virus disease. Clin Vaccine Immunol 23(3):189\u2013195. https:\/\/doi.org\/10.1128\/CVI.00609-15","journal-title":"Clin Vaccine Immunol"},{"issue":"9","key":"3221_CR2","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","volume":"12","author":"AS Agrawal","year":"2016","unstructured":"Agrawal AS, Tao X, Algaissi A, Garron T, Narayanan K, Peng BH, Couch RB, Tseng CT (2016) Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother 12(9):2351\u20132356. https:\/\/doi.org\/10.1080\/21645515.2016.1177688","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"3221_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/00368504211025927","volume":"104","author":"W Alam","year":"2021","unstructured":"Alam W (2021) COVID-19 vaccine-induced immune thrombotic thrombocytopenia: a review of the potential mechanisms and proposed management. Sci Prog 104(2):1\u201313. https:\/\/doi.org\/10.1177\/00368504211025927","journal-title":"Sci Prog"},{"issue":"7821","key":"3221_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41586-020-2538-8","volume":"584","author":"AM Arvin","year":"2020","unstructured":"Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R, Havenar-Daughton C, Lanzavecchia A, Corti D, Virgin HW (2020) A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature 584(7821):353\u2013363. https:\/\/doi.org\/10.1038\/s41586-020-2538-8","journal-title":"Nature"},{"issue":"23","key":"3221_CR5","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1056\/NEJMe2106315","volume":"384","author":"DB Cines","year":"2021","unstructured":"Cines DB, Bussel JB (2021) SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med 384(23):2254\u20132256. https:\/\/doi.org\/10.1056\/NEJMe2106315","journal-title":"N Engl J Med"},{"issue":"Pt 1","key":"3221_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1099\/0022-1317-83-1-151","volume":"83","author":"CJ Cohen","year":"2002","unstructured":"Cohen CJ, Xiang ZQ, Gao GP, Ertl H, Wilson JM, Bergelson JM (2002) Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. J Gen Virol 83(Pt 1):151\u2013155. https:\/\/doi.org\/10.1099\/0022-1317-83-1-151","journal-title":"J Gen Virol"},{"key":"3221_CR7","unstructured":"EMA (2010) CHMP\/VWP\/141697\/2009 Guideline on quality, nonclinical and clinical aspects of live recombinant viral vectored vaccine. https:\/\/www.ema.europa.eu\/en\/quality-non-clinical-clinical-aspects-live-recombinant-viral-vectored-vaccines. Accessed 7 Nov 2021"},{"key":"3221_CR8","doi-asserted-by":"publisher","first-page":"t4986","DOI":"10.1101\/pdb.prot4986","volume":"2008","author":"AH Fischer","year":"2008","unstructured":"Fischer AH, Jacobson KA, Rose J, Zeller R (2008) Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc 2008:t4986. https:\/\/doi.org\/10.1101\/pdb.prot4986","journal-title":"CSH Protoc"},{"issue":"12","key":"3221_CR9","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1001\/jama.202.12.1075","volume":"202","author":"VA Fulginiti","year":"1967","unstructured":"Fulginiti VA, Eller JJ, Downie AW, Kempe CH (1967) Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 202(12):1075\u20131080. https:\/\/doi.org\/10.1001\/jama.202.12.1075","journal-title":"JAMA"},{"issue":"11","key":"3221_CR10","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/nm952","volume":"9","author":"A Gaggar","year":"2003","unstructured":"Gaggar A, Shayakhmetov DM, Lieber A (2003) CD46 is a cellular receptor for group B adenoviruses. Nat Med 9(11):1408\u20131412. https:\/\/doi.org\/10.1038\/nm952","journal-title":"Nat Med"},{"issue":"6494","key":"3221_CR11","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1126\/science.abb8923","volume":"368","author":"BS Graham","year":"2020","unstructured":"Graham BS (2020) Rapid COVID-19 vaccine development. Science 368(6494):945\u2013946. https:\/\/doi.org\/10.1126\/science.abb8923","journal-title":"Science"},{"issue":"11","key":"3221_CR12","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1111\/jth.13813","volume":"15","author":"A Greinacher","year":"2017","unstructured":"Greinacher A, Selleng K, Warkentin TE (2017) Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost 15(11):2099\u20132114. https:\/\/doi.org\/10.1111\/jth.13813","journal-title":"J Thromb Haemost"},{"issue":"22","key":"3221_CR13","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S (2021) Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med 384(22):2092\u20132101. https:\/\/doi.org\/10.1056\/NEJMoa2104840","journal-title":"N Engl J Med"},{"key":"3221_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe0948","author":"BF Haynes","year":"2020","unstructured":"Haynes BF, Corey L, Fernandes P, Gilbert PB, Hotez PJ, Rao S, Santos MR, Schuitemaker H, Watson M, Arvin A (2020) Prospects for a safe COVID-19 vaccine. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abe0948","journal-title":"Sci Transl Med"},{"key":"3221_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","volume":"4","author":"C Herve","year":"2019","unstructured":"Herve C, Laupeze B, Del GG, Didierlaurent AM, Tavares DSF (2019) The how\u2019s and what\u2019s of vaccine reactogenicity. Npj Vaccines 4:39. https:\/\/doi.org\/10.1038\/s41541-019-0132-6","journal-title":"Npj Vaccines"},{"issue":"2","key":"3221_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1586\/14760584.2016.1115353","volume":"15","author":"PA Jorquera","year":"2016","unstructured":"Jorquera PA, Anderson L, Tripp RA (2016) Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis. Expert Rev Vaccines 15(2):173\u2013187. https:\/\/doi.org\/10.1586\/14760584.2016.1115353","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"3221_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","volume":"89","author":"HW Kim","year":"1969","unstructured":"Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89(4):422\u2013434. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a120955","journal-title":"Am J Epidemiol"},{"key":"3221_CR18","doi-asserted-by":"publisher","first-page":"697074","DOI":"10.3389\/fimmu.2021.697074","volume":"12","author":"M Li","year":"2021","unstructured":"Li M, Guo J, Lu S, Zhou R, Shi H, Shi X, Cheng L, Liang Q, Liu H, Wang P et al (2021) Single-dose immunization with a chimpanzee adenovirus-based vaccine induces sustained and protective immunity against SARS-CoV-2 infection. Front Immunol 12:697074. https:\/\/doi.org\/10.3389\/fimmu.2021.697074","journal-title":"Front Immunol"},{"issue":"10275","key":"3221_CR19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS et al (2021) Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397(10275):671\u2013681. https:\/\/doi.org\/10.1016\/S0140-6736(21)00234-8","journal-title":"Lancet"},{"issue":"1","key":"3221_CR20","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1002\/cpph.43","volume":"83","author":"JR Mathiasen","year":"2018","unstructured":"Mathiasen JR, Moser VC (2018) The Irwin test and functional observational battery (FOB) for assessing the effects of compounds on behavior, physiology, and safety pharmacology in rodents. Curr Protoc Pharmacol 83(1):e43. https:\/\/doi.org\/10.1002\/cpph.43","journal-title":"Curr Protoc Pharmacol"},{"issue":"20","key":"3221_CR21","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1056\/NEJMc2105869","volume":"384","author":"KL Muir","year":"2021","unstructured":"Muir KL, Kallam A, Koepsell SA, Gundabolu K (2021) Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med 384(20):1964\u20131965. https:\/\/doi.org\/10.1056\/NEJMc2105869","journal-title":"N Engl J Med"},{"issue":"22","key":"3221_CR22","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1016\/j.vaccine.2021.01.055","volume":"39","author":"FM Munoz","year":"2021","unstructured":"Munoz FM, Cramer JP, Dekker CL, Dudley MZ, Graham BS, Gurwith M, Law B, Perlman S, Polack FP, Spergel JM et al (2021) Vaccine-associated enhanced disease: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 39(22):3053\u20133066. https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.055","journal-title":"Vaccine"},{"issue":"7","key":"3221_CR23","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1182\/blood-2006-06-032524","volume":"109","author":"M Othman","year":"2007","unstructured":"Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D (2007) Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 109(7):2832\u20132839. https:\/\/doi.org\/10.1182\/blood-2006-06-032524","journal-title":"Blood"},{"issue":"6","key":"3221_CR24","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/jat.3941","volume":"40","author":"C Planty","year":"2020","unstructured":"Planty C, Chevalier G, Duclos ME, Chalmey C, Thirion-Delalande C, Sobry C, Steff AM, Destexhe E (2020) Nonclinical safety assessment of repeated administration and biodistribution of ChAd3-EBO-Z Ebola candidate vaccine. J Appl Toxicol 40(6):748\u2013762. https:\/\/doi.org\/10.1002\/jat.3941","journal-title":"J Appl Toxicol"},{"issue":"9","key":"3221_CR25","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm918","volume":"9","author":"FP Polack","year":"2003","unstructured":"Polack FP, Hoffman SJ, Crujeiras G, Griffin DE (2003) A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med 9(9):1209\u20131213. https:\/\/doi.org\/10.1038\/nm918","journal-title":"Nat Med"},{"issue":"3","key":"3221_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.immuni.2019.08.007","volume":"51","author":"TJ Ruckwardt","year":"2019","unstructured":"Ruckwardt TJ, Morabito KM, Graham BS (2019) Immunological lessons from respiratory syncytial virus vaccine development. Immunity 51(3):429\u2013442. https:\/\/doi.org\/10.1016\/j.immuni.2019.08.007","journal-title":"Immunity"},{"issue":"23","key":"3221_CR27","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B et al (2021) Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 384(23):2187\u20132201. https:\/\/doi.org\/10.1056\/NEJMoa2101544","journal-title":"N Engl J Med"},{"issue":"23","key":"3221_CR28","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","volume":"384","author":"M Scully","year":"2021","unstructured":"Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, Goldblatt D, Kotoucek P, Thomas W, Lester W (2021) Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med 384(23):2202\u20132211. https:\/\/doi.org\/10.1056\/NEJMoa2105385","journal-title":"N Engl J Med"},{"issue":"3","key":"3221_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/15376510802312464","volume":"5","author":"RL Sheets","year":"2008","unstructured":"Sheets RL, Stein J, Bailer RT, Koup RA, Andrews C, Nason M, He B, Koo E, Trotter H, Duffy C et al (2008) Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer\u2019s construct, or gene inserts. J Immunotoxicol 5(3):315\u2013335. https:\/\/doi.org\/10.1080\/15376510802312464","journal-title":"J Immunotoxicol"},{"issue":"1","key":"3221_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/jps.21088","volume":"97","author":"MP Vinardell","year":"2008","unstructured":"Vinardell MP, Mitjans M (2008) Alternative methods for eye and skin irritation tests: an overview. J Pharm Sci 97(1):46\u201359. https:\/\/doi.org\/10.1002\/jps.21088","journal-title":"J Pharm Sci"},{"issue":"10269","key":"3221_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens S, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269):99\u2013111. https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1","journal-title":"Lancet"},{"issue":"4","key":"3221_CR32","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","volume":"181","author":"Q Wang","year":"2020","unstructured":"Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen KY et al (2020) Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 181(4):894\u2013904. https:\/\/doi.org\/10.1016\/j.cell.2020.03.045","journal-title":"Cell"},{"key":"3221_CR33","unstructured":"WHO (2005) Technical Report Series no. 927 Annex 1-WHO guidelines on non clinical evaluation of vaccines. https:\/\/www.who.int\/publications\/m\/item\/annex1-nonclinical.p31-63. Accessed 7 Nov. 2021"},{"issue":"9","key":"3221_CR34","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","volume":"181","author":"F Yasui","year":"2008","unstructured":"Yasui F, Kai C, Kitabatake M, Inoue S, Yoneda M, Yokochi S, Kase R, Sekiguchi S, Morita K, Hishima T et al (2008) Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol 181(9):6337\u20136348. https:\/\/doi.org\/10.4049\/jimmunol.181.9.6337","journal-title":"J Immunol"},{"issue":"8","key":"3221_CR35","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/14760584.2020.1800463","volume":"19","author":"RM Zellweger","year":"2020","unstructured":"Zellweger RM, Wartel TA, Marks F, Song M, Kim JH (2020) Vaccination against SARS-CoV-2 and disease enhancement\u2014knowns and unknowns. Expert Rev Vaccines 19(8):691\u2013698. https:\/\/doi.org\/10.1080\/14760584.2020.1800463","journal-title":"Expert Rev Vaccines"},{"issue":"10249","key":"3221_CR36","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","volume":"396","author":"FC Zhu","year":"2020","unstructured":"Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ et al (2020) Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 396(10249):479\u2013488. https:\/\/doi.org\/10.1016\/S0140-6736(20)31605-6","journal-title":"Lancet"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-021-03221-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-021-03221-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-021-03221-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T20:05:31Z","timestamp":1650312331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-021-03221-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["3221"],"URL":"https:\/\/doi.org\/10.1007\/s00204-021-03221-x","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]},"assertion":[{"value":"16 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All animal experiment protocols were reviewed and approved by the Institutional Animal Care and Use Committee of Center for New Drug Safety Evaluation and Research, China Pharmaceutical University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}